HR 756, a New Cephalosporin Active Against Gram-Positive and Gram-Negative Aerobic and Anaerobic Bacteria

1979/02/01 by Harold C. Neu, Nalinee Aswapokee, Prasit Aswapokee +2
Biochemistry, Genetics and Molecular Biology · Chemistry · #Antibiotic Resistance in Bacteria #Phenothiazines and Benzothiazines Synthesis and Activities #Synthesis of β-Lactam Compounds

paper · doi:10.1128/aac.15.2.273

Abstract

The in vitro activity of HR 756, 7-[2-(2-amino-4-thiazolyl)-2-(Z)-(methoximino)acetamido] cephalosporanic acid, was investigated against 659 isolates. HR 756 inhibited Neisseria and Haemophilus species at concentrations similar to those needed with ampicillin. It inhibited beta-lactamase-producing N. gonorrhoeae and H. influenzae. HR 756 was the most active compound tested against members of the Enterobacteriaceae, inhibiting most isolates of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Salmonella, Enterobacter, and Shigella at concentrations of less than 0.1 mug/ml. It was twice as active as carbenicillin against Pseudomonas aeruginosa and inhibited Bacteroides fragilis as well as cefoxitin. HR 756 killed E. coli, Staphylococcus aureus, and P. aeruginosa at rates similar to other beta-lactam antibiotics.

Related

• In vitro activity and beta-lactamase stability of GR69153, a new long-acting cephalosporin
• In vitro and in vivo antibacterial activities of FK037, a novel parenteral broad-spectrum cephalosporin
• Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It
• Bacterial Antibiotic Resistance: The Most Critical Pathogens
• Revitalizing cephalosporins: The promise of β-lactamase inhibitor combinations